NCT01098474View on ClinicalTrials.gov

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

July 7, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

March 16, 2012

Conditions
Tuberculosis
Interventions
BIOLOGICAL

GSK's investigational vaccine 692342

Intramuscular, 1 or 2 doses

BIOLOGICAL

Tritanrix™ HB+Hib

Intramuscular, 3 doses

BIOLOGICAL

Prevnar™

Intramuscular, 3 doses

BIOLOGICAL

Polio Sabin™

Oral, 3 doses

BIOLOGICAL

Menjugate™

Intramuscular, 3 doses

Trial Locations (1)

Unknown

GSK Investigational Site, Banjul

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

Aeras
All Listed Sponsors
collaborator

Aeras

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT01098474 - Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants | Biotech Hunter | Biotech Hunter